<DOC>
	<DOC>NCT01068756</DOC>
	<brief_summary>The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin</brief_summary>
	<brief_title>Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy subjects Body Mass Index (BMI) of 18 to 32 inclusive Women who are not of childbearing potential and men, ages 18 to 45 Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations Glucosuria Abnormal liver function tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>